Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

2.

Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.

Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, Malmberg A, Persson BE.

Eur Urol. 2014 Dec;66(6):1101-8. doi: 10.1016/j.eururo.2013.12.063.

PMID:
24440304
3.

Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.

Van Poppel H, Klotz L.

Int J Urol. 2012 Jul;19(7):594-601. doi: 10.1111/j.1442-2042.2012.02997.x. Review.

4.

Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.

Boccon-Gibod L, Iversen P, Persson BE.

Expert Rev Anticancer Ther. 2009 Dec;9(12):1737-43. doi: 10.1586/era.09.150.

PMID:
19954284
5.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.

BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.

6.

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE.

J Urol. 2011 Sep;186(3):889-97. doi: 10.1016/j.juro.2011.04.083.

PMID:
21788033
7.

Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide.

Iversen P, Karup C, van der Meulen E, Tankó LB, Huhtaniemi I.

Prostate Cancer Prostatic Dis. 2011 Jun;14(2):184-90. doi: 10.1038/pcan.2011.11.

PMID:
21445092
8.

Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.

Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC.

Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):261-70. doi: 10.1586/erp.13.13.

PMID:
23570437
9.

Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.

Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AA.

J Urol. 2010 Dec;184(6):2313-9. doi: 10.1016/j.juro.2010.08.012.

10.

Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.

Klotz L.

Expert Opin Drug Metab Toxicol. 2015;11(11):1795-802. doi: 10.1517/17425255.2015.1085506. Review.

PMID:
26513436
12.

GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model.

Hopmans SN, Duivenvoorden WC, Werstuck GH, Klotz L, Pinthus JH.

Urol Oncol. 2014 Nov;32(8):1126-34. doi: 10.1016/j.urolonc.2014.06.018.

PMID:
25242517
13.

A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.

Lee D, Porter J, Gladwell D, Brereton N, Nielsen SK.

J Med Econ. 2014 Apr;17(4):233-47. doi: 10.3111/13696998.2014.893240.

PMID:
24568188
14.

Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.

Kirby RS, Fitzpatrick JM, Clarke N.

BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x. Review.

15.
16.

Degarelix: a new approach for the treatment of prostate cancer.

Persson BE, Kold Olesen T, Jensen JK.

Neuroendocrinology. 2009;90(3):235-44. doi: 10.1159/000228832.

PMID:
19602868
17.

Degarelix and its therapeutic potential in the treatment of prostate cancer.

Doehn C, Sommerauer M, Jocham D.

Clin Interv Aging. 2009;4:215-23. Review.

18.

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.

Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG.

Urology. 1999 May;53(5):898-902; discussion 902-3.

PMID:
10223480
20.

The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.

Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ.

J Urol. 2006 Aug;176(2):520-5.

PMID:
16813881
Items per page

Supplemental Content

Support Center